Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands
Introduction Psoriasis is a chronic inflammatory condition that can significantly impact the quality of life (QoL), regardless of the level of skin involvement. Apremilast is indicated for the treatment of moderate to severe psoriasis. Real-world data regarding the impact of apremilast on patient-reported outcomes in clinical practice in the Netherlands is lacking. Methods The prospective, multicenter observational Apremilast in Real-Life Psoriasis Treatment (APRIL) study enrolled patients ≥ 18 years old with moderate to severe plaque psoriasis receiving apremilast in clinical practice in the Netherlands. Patients were followed-up for 12 months, with assessments scheduled at 6 and 12 months. The primary outcome was Dermatology Life Quality Index (DLQI) response (score ≤ 5 or ≥ 5-point improvement from baseline) at 6 months. Secondary patient-reported outcomes included EQ-5D and skin-specific parameters; exploratory outcomes were Patient Benefit Index (PBI) and Work Productivity and Activity Impairment (WPAI). Results Of the 155 patients enrolled (February 2016–June 2019), 153 received apremilast; 69 (45%) and 39 (26%) continued treatment at 6 and 12 months, respectively. Psoriasis in special areas was common (scalp, 65%; nail, 51%; palmoplantar, 27%). Most patients (92%) had received prior systemic antipsoriatic therapies. Of the 151 patients with a baseline DLQI value, 56 (37%) achieved DLQI response at 6 months. Mean (standard deviation) PBI scores were 3.5 (1.2) and 3.8 (1.1) at 6 and 12 months, respectively. Improvements in DLQI, EQ-5D, and WPAI scores and disease signs and symptoms, including itch and special areas, were observed at 6 and 12 months. Adverse events were consistent with the known safety profile. Conclusions In the Netherlands, patients with moderate to severe psoriasis receiving apremilast for up to 12 months reported improved disease-related QoL, skin involvement, and patient-reported outcomes. These data add to the growing body of evidence demonstrating apremilast is an effective treatment for psoriasis, itch, and special areas (scalp and palms). Trial Registration ClinicalTrials.gov, NCT02652494..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Advances in therapy - 41(2024), 4 vom: 24. Feb., Seite 1594-1605 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van den Reek, Juul M. P. A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Apremilast |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s12325-023-02759-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055270158 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055270158 | ||
| 003 | DE-627 | ||
| 005 | 20240325061004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-023-02759-9 |2 doi | |
| 035 | |a (DE-627)SPR055270158 | ||
| 035 | |a (SPR)s12325-023-02759-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a van den Reek, Juul M. P. A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Introduction Psoriasis is a chronic inflammatory condition that can significantly impact the quality of life (QoL), regardless of the level of skin involvement. Apremilast is indicated for the treatment of moderate to severe psoriasis. Real-world data regarding the impact of apremilast on patient-reported outcomes in clinical practice in the Netherlands is lacking. Methods The prospective, multicenter observational Apremilast in Real-Life Psoriasis Treatment (APRIL) study enrolled patients ≥ 18 years old with moderate to severe plaque psoriasis receiving apremilast in clinical practice in the Netherlands. Patients were followed-up for 12 months, with assessments scheduled at 6 and 12 months. The primary outcome was Dermatology Life Quality Index (DLQI) response (score ≤ 5 or ≥ 5-point improvement from baseline) at 6 months. Secondary patient-reported outcomes included EQ-5D and skin-specific parameters; exploratory outcomes were Patient Benefit Index (PBI) and Work Productivity and Activity Impairment (WPAI). Results Of the 155 patients enrolled (February 2016–June 2019), 153 received apremilast; 69 (45%) and 39 (26%) continued treatment at 6 and 12 months, respectively. Psoriasis in special areas was common (scalp, 65%; nail, 51%; palmoplantar, 27%). Most patients (92%) had received prior systemic antipsoriatic therapies. Of the 151 patients with a baseline DLQI value, 56 (37%) achieved DLQI response at 6 months. Mean (standard deviation) PBI scores were 3.5 (1.2) and 3.8 (1.1) at 6 and 12 months, respectively. Improvements in DLQI, EQ-5D, and WPAI scores and disease signs and symptoms, including itch and special areas, were observed at 6 and 12 months. Adverse events were consistent with the known safety profile. Conclusions In the Netherlands, patients with moderate to severe psoriasis receiving apremilast for up to 12 months reported improved disease-related QoL, skin involvement, and patient-reported outcomes. These data add to the growing body of evidence demonstrating apremilast is an effective treatment for psoriasis, itch, and special areas (scalp and palms). Trial Registration ClinicalTrials.gov, NCT02652494. | ||
| 650 | 4 | |a Apremilast |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dermatology Life Quality Index |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a DLQI |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Patient Benefit Index |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Patient-reported outcomes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Psoriasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Quality of life |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Real-world evidence |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a van der Leest, Robert J. T. |4 aut | |
| 700 | 1 | |a Thomas, Sarah E. |0 (orcid)0000-0002-1343-353X |4 aut | |
| 700 | 1 | |a Prevoo, Ruud |4 aut | |
| 700 | 1 | |a Plantenga, Margreet E. |4 aut | |
| 700 | 1 | |a de Jong, Elke M. G. J. |0 (orcid)0000-0003-3872-5704 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Springer Healthcare, 2000 |g 41(2024), 4 vom: 24. Feb., Seite 1594-1605 |w (DE-627)SPR024919926 |w (DE-600)2421646-X |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:24 |g month:02 |g pages:1594-1605 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12325-023-02759-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 4 |b 24 |c 02 |h 1594-1605 | ||